3-D Sys Corp Del Stock Price, News & Analysis

3D Systems has successfully completed an upsized offering of $460 million in 0% convertible senior notes due 2026. The offering includes $60 million from the initial purchasers' option. The notes do not accrue interest and will mature on November 15, 2026. They have an initial conversion rate of 27.8364 shares per $1,000 principal amount, representing a 42.5% premium over the recent stock price. Net proceeds of approximately $446 million will be used for general corporate purposes, including potential acquisitions. The offering was made to qualified institutional buyers under Rule 144A.

3D Systems (NYSE: DDD) has unveiled several innovations aimed at advancing additive manufacturing across healthcare and industrial sectors. Key highlights include the launch of the SLS 380 for enhanced part production, the DMP Flex 350 Dual and DMP Factory 350 Dual which reduce build times significantly, and the DMP Flex 200 optimized for dental applications. Additional advancements include the 3DXpert® 17 software for improved design workflows and the Figure 4® Rigid 140C Black material for automotive applications, showcasing the company's commitment to delivering innovative solutions in 3D printing.

3D Systems has priced its offering of $400 million in 0% convertible senior notes due 2026, raising the initial offering from $350 million. The sale is expected to close on November 16, 2021. The notes, with a conversion rate of 27.8364 shares per $1,000 principal, represent a 42.5% premium over the recent stock price. Estimated net proceeds are around $388 million, intended for general corporate purposes, including potential acquisitions. The offering is made under Rule 144A and involves risks that could affect the company's future performance.

3D Systems announced a proposed offering of $350 million of convertible senior notes due 2026. An additional $52.5 million may be purchased by initial investors within 13 days of issuance. The notes will be unsecured and interest will be paid semiannually. They can be converted under certain conditions until 2026, upon which 3D Systems may pay cash, stock, or a combination upon conversion. The net proceeds will support general corporate purposes, including potential acquisitions. This offering is private and subject to market conditions.

3D Systems Corporation (NYSE:DDD) reported Q3 2021 revenue of $156.1 million, reflecting a 14.6% increase year-over-year. Adjusted for divestitures, revenue grew 35.9% compared to 2020. The company achieved a 10.5% adjusted EBITDA margin and generated $20.7 million in positive cash flow, marking four consecutive quarters of positive operations. Following divestitures, cash reserves stand at $502.8 million with no debt. 3D Systems announced acquisitions of Oqton and Volumetric Biotechnologies to drive future high-margin growth. Gross profit margin was 41.2%.

3D Systems announces an expansion of its collaboration with United Therapeutics to develop bioprinting technology for multiple human organs, beyond just lungs. This amendment will take effect once 3D Systems completes its acquisition of Volumetric Biotechnologies, Inc. The program aims to provide an unlimited supply of biocompatible human organs for transplantation, relying on a technology platform established since 2017. The initiative is projected to continue through 2025, reflecting the companies' commitment to addressing urgent medical needs for organ transplants.

Volumetric, a Houston-based biofabrication start-up, has been acquired by 3D Systems (NYSE: DDD) for an initial payment of $45 million, with potential milestone earnouts up to $355 million. The acquisition aims to advance bioprinting technology for human organ replacement, enhancing regenerative medicine capabilities. Volumetric's 20,000 sq. ft. facility will be established in Houston's East End Maker Hub. This deal strengthens 3D Systems' partnership with United Therapeutics Corporation (NASDAQ: UTHR) for organ therapy development.

3D Systems has announced the acquisition of Volumetric Biotechnologies for an initial payment of $45 million, with a potential total value of $400 million tied to future performance milestones. This acquisition aims to enhance 3D Systems’ capabilities in the bioprinting of human organs, particularly focusing on the liver and other applications. Dr. Jordan Miller will join as Chief Scientist for Regenerative Medicine to lead this initiative, expanding the company's efforts alongside United Therapeutics in creating vital organ solutions. A conference call on October 28, 2021, will provide further details.

3D Systems (DDD) announced that it will release its third quarter 2021 financial results and file its Form 10-Q on November 8, 2021, after U.S. markets close. A conference call to discuss these results will take place on November 9, 2021, at 8:30 a.m. ET. Investors can participate via telephone or webcast. The company emphasizes its reliance on forward-looking statements, cautioning that actual results may differ due to various risks and uncertainties. More details can be found on their investor relations webpage.